文献速递心境障碍焦虑、强迫与应激相关障碍

舍曲林在初级保健中的临床疗效及抑郁严重程度和病程的作用(PANDA):实用、双盲、安慰剂对照随机试验

The clinical effectiveness of sertraline in primary care and the role of depression severity and duration (PANDA): a pragmatic, double-blind, placebo-controlled randomised trial.
PubMed 文献 · Lancet Psychiatry · 2019-09-19

PANDA研究为实用、多中心、双盲、安慰剂对照随机试验,纳入英国四城市179家初级保健机构中18-74岁、过去2年有任意严重程度或病程的抑郁症状且临床对使用抗抑郁药获益不确定的患者。655例随机分入舍曲林组(326例)或安慰剂组(329例),主要结局为6周时PHQ-9抑郁症状。

要点

  • 6周时舍曲林组与安慰剂组PHQ-9评分无显著差异,未达临床意义。
  • 舍曲林改善了焦虑症状、精神健康相关生活质量和自评心理健康。
  • 不良事件两组无差异,支持在更广泛人群中处方SSRI。

核心结论

  • 舍曲林在初级保健中6周内不太可能减轻抑郁症状,但焦虑、生活质量和自评心理健康有临床重要改善。
  • 研究支持在比既往更广泛的人群中处方SSRI抗抑郁药,包括不符合抑郁症或广泛性焦虑障碍诊断标准的轻中度症状患者。

研究设计与样本

  • PANDA研究为实用、多中心、双盲、安慰剂对照随机试验,纳入英国四城市179家初级保健机构。
  • 纳入18-74岁、过去2年有任意严重程度或病程的抑郁症状且临床对使用抗抑郁药获益不确定的患者,共655例随机分入舍曲林组(326例)或安慰剂组(329例)。
  • 舍曲林50 mg或安慰剂每日1粒胶囊1周,然后每日2粒胶囊至11周;主要结局为随机化后6周PHQ-9抑郁症状。
  • 分析为意向性治疗,主要结局分析纳入550例(舍曲林组266例,安慰剂组284例;85%随访)。

主要发现

  • 舍曲林组在焦虑症状、精神健康相关生活质量(而非躯体健康相关生活质量)及自评心理健康改善方面优于安慰剂。
  • 12周时舍曲林减轻抑郁症状的证据较弱。
  • 记录7例不良事件(舍曲林组4例,安慰剂组3例),两组无差异;3例严重不良事件(舍曲林组2例,安慰剂组1例),其中舍曲林组1例严重不良事件可能与研究药物相关。

临床怎么用

  • 在初级保健中,对抑郁症状患者处方舍曲林时,6周内不应期望抑郁症状显著减轻,但可关注焦虑和生活质量的改善。
  • 研究支持SSRI可用于更广泛的患者群体,包括轻中度症状且不符合抑郁症或广泛性焦虑障碍诊断标准者。

局限性

  • 主要结局分析因失访仅纳入550例(85%随访),可能影响结果解释。
  • 12周时抑郁症状减轻的证据较弱。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Depression is usually managed in primary care, but most antidepressant trials are of patients from secondary care mental health services, with eligibility criteria based on diagnosis and severity of depressive symptoms. Antidepressants are now used in a much wider group of people than in previous regulatory trials. We investigated the clinical effectiveness of sertraline in patients in primary care with depressive symptoms ranging from mild to severe and tested the role of severity and duration in treatment response. METHODS: The PANDA study was a pragmatic, multicentre, double-blind, placebo-controlled randomised trial of patients from 179 primary care surgeries in four UK cities (Bristol, Liverpool, London, and York). We included patients aged 18 to 74 years who had depressive symptoms of any severity or duration in the past 2 years, where there was clinical uncertainty about the benefit of an antidepressant. This strategy was designed to improve the generalisability of our sample to current use of antidepressants within primary care. Patients were randomly assigned (1:1) with a remote computer-generated code to sertraline or placebo, and were stratified by severity, duration, and site with random block length. Patients received one capsule (sertraline 50 mg or placebo orally) daily for one week then two capsules daily for up to 11 weeks, consistent with evidence on optimal dosages for efficacy and acceptability. The primary outcome was depressive symptoms 6 weeks after randomisation, measured by Patient Health Questionnaire, 9-item version (PHQ-9) scores. Secondary outcomes at 2, 6 and 12 weeks were depressive symptoms and remission (PHQ-9 and Beck Depression Inventory-II), generalised anxiety symptoms (Generalised Anxiety Disorder Assessment 7-item version), mental and physical health-related quality of life (12-item Short-Form Health Survey), and self-reported improvement. All analyses compared groups as randomised (intention-to-treat). The study is registered with EudraCT, 2013-003440-22 (protocol number 13/0413; version 6.1) and ISRCTN, ISRCTN84544741, and is closed to new participants. FINDINGS: Between Jan 1, 2015, and Aug 31, 2017, we recruited and randomly assigned 655 patients-326 (50%) to sertraline and 329 (50%) to placebo. Two patients in the sertraline group did not complete a substantial proportion of the baseline assessment and were excluded, leaving 653 patients in total. Due to attrition, primary outcome analyses were of 550 patients (266 in the sertraline group and 284 in the placebo group; 85% follow-up that did not differ by treatment allocation). We found no evidence that sertraline led to a clinically meaningful reduction in depressive symptoms at 6 weeks. The mean 6-week PHQ-9 score was 7·98 (SD 5·63) in the sertraline group and 8·76 (5·86) in the placebo group (adjusted proportional difference 0·95, 95% CI 0·85-1·07; p=0·41). However, for secondary outcomes, we found evidence that sertraline led to reduced anxiety symptoms, better mental (but not physical) health-related quality of life, and self-reported improvements in mental health. We observed weak evidence that depressive symptoms were reduced by sertraline at 12 weeks. We recorded seven adverse events-four for sertraline and three for placebo, and adverse events did not differ by treatment allocation. Three adverse events were classified as serious-two in the sertraline group and one in the placebo group. One serious adverse event in the sertraline group was classified as possibly related to study medication. INTERPRETATION: Sertraline is unlikely to reduce depressive symptoms within 6 weeks in primary care but we observed improvements in anxiety, quality of life, and self-rated mental health, which are likely to be clinically important. Our findings support the prescription of SSRI antidepressants in a wider group of participants than previously thought, including those with mild to moderate symptoms who do not meet diagnostic criteria for depression or generalised anxiety disorder. FUNDING: National Institute for Health Research.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Lewis G, Duffy L, Ades A, et al. The clinical effectiveness of sertraline in primary care and the role of depression severity and duration (PANDA): a pragmatic, double-blind, placebo-controlled randomised trial. Lancet Psychiatry. 2019. PMID: 31543474. doi:10.1016/S2215-0366(19)30366-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。